HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a research report released on Tuesday morning, Marketbeat Ratings reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the company. Zacks Investment Research raised Celldex Therapeutics from a hold rating to a buy rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. Aegis reissued a buy rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. ValuEngine lowered Celldex Therapeutics from a sell rating to a strong sell rating in a research note on Saturday, June 3rd. Jefferies Group LLC reissued a hold rating and set a $3.50 price target (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Finally, Cowen and Company reissued a buy rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of Hold and an average price target of $7.32.

Shares of Celldex Therapeutics (CLDX) traded down 1.95% during mid-day trading on Tuesday, reaching $2.52. The company’s stock had a trading volume of 805,966 shares. The company has a 50-day moving average of $2.44 and a 200-day moving average of $3.05. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The firm’s market cap is $315.26 million.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.28). Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.57 million. On average, analysts predict that Celldex Therapeutics will post ($1.10) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/04/celldex-therapeutics-cldx-buy-rating-reiterated-at-hc-wainwright.html.

Several institutional investors have recently bought and sold shares of CLDX. Parametric Portfolio Associates LLC raised its position in Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 1,409 shares in the last quarter. Teachers Advisors LLC raised its position in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 1,433 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 2,453 shares in the last quarter. American International Group Inc. raised its position in Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares in the last quarter. Finally, Creative Planning raised its position in Celldex Therapeutics by 6.1% in the first quarter. Creative Planning now owns 71,420 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 4,084 shares in the last quarter. 65.85% of the stock is currently owned by institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.